FOR IMMEDIATE RELEASE

CONTACT: Joni Avery
Susan G. Komen
972-855-4382
press@komen.org

SUSAN G. KOMEN®-FUNDED RESEARCH SHOWS PROMISE IN SLOWING, STOPPING
METASTATIC BREAST CANCER

Work Led by Komen-Funded Young Investigator Reveals More about Role of RAGE in Breast
Cancer Metastasis

DALLAS – September 29, 2016 – A research grant awarded by Susan G. Komen in 2015 is breaking
new ground in the understanding of metastatic breast cancer. Dr. Barry I. Hudson, cancer researcher at
Sylvester Comprehensive Cancer Center (part of UHealth – the University of Miami Health System), and
team found that blocking expression of Receptor for Advanced Glycation End-products (RAGE) in breast
cancer cells led to a decrease in the cells’ ability to invade surrounding tissue. They also showed in both
human cells and mouse models that blocking RAGE decreased tumor growth and reduced tumor
angiogenesis (development of new blood vessels). In addition, blocking RAGE also reduced the
recruitment of inflammatory cells and dramatically decreased metastasis to both the lungs and liver in
mouse models of breast cancer.

These data demonstrate that RAGE drives tumor progression and metastasis, and may represent a novel
target for the development of new therapies for metastatic breast cancer.

“To achieve our organization’s new Bold Goal to decrease the current number of breast cancer deaths by
50 percent in the U.S. over the next decade, we need significant breakthroughs in the treatment of
metastatic breast cancer. The work of Dr. Hudson and his team is an important step to take on the form of
the disease that claims 40,000 lives annually,” said Komen President and CEO Dr. Judy Salerno.

“These significant findings also underscore the need for continuous support of research funding for young
investigators hoping to launch a career in breast cancer research, like Dr. Hudson, who received a Career
Catalyst Research grant last year. The next generation of breast cancer researchers will be the ones to
bring us the cures, and we must ensure they are able to pursue their work,” Dr. Salerno added.

Komen recently announced $32.7 million in new research funding, nearly 40 percent of which is focused
on metastatic research. To date, the organization has invested more than $166 million in over 400
research grants and more than 40 clinical trials focused on metastatic breast cancer.

Read more about the new findings in Oncogene.

About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization outside of the federal government,
funding more breast cancer research than any other nonprofit while providing real-time help to those
facing the disease. Since its founding in 1982, Komen has funded more than $920 million in research and
provided more than $2 billion in funding to screening, education, treatment and psychosocial support
programs. Komen has worked in more than 60 countries worldwide. Komen was founded by Nancy G.
Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social